Form 8-K - Current report:
SEC Accession No. 0000950170-23-039043
Filing Date
2023-08-07
Accepted
2023-08-07 16:05:17
Documents
12
Period of Report
2023-08-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K asmb-20230804.htm   iXBRL 8-K 63169
  Complete submission text file 0000950170-23-039043.txt   184511

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT asmb-20230804_pre.xml EX-101.PRE 10679
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT asmb-20230804.xsd EX-101.SCH 2483
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT asmb-20230804_lab.xml EX-101.LAB 17018
6 EXTRACTED XBRL INSTANCE DOCUMENT asmb-20230804_htm.xml XML 4546
Mailing Address 331 OYSTER POINT BLVD. FOURTH FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 331 OYSTER POINT BLVD. FOURTH FLOOR SOUTH SAN FRANCISCO CA 94080 (833) 409-4583
ASSEMBLY BIOSCIENCES, INC. (Filer) CIK: 0001426800 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35005 | Film No.: 231147558
SIC: 2834 Pharmaceutical Preparations